Search research articles
Contact Us
Filters
Showing results (71-80 of 116) with videos related to
Page
of 12
Sort By:
Clinical Epigenetics
|
September 24, 2016
<i>SEPT9</i> and <i>SHOX2</i> DNA methylation status and its utility in the diagnosis of colonic adenomas and colorectal adenocarcinomas
Alexander Semaan, Anne van Ellen, Sebastian Meller, et al.
Oncotarget
|
October 8, 2016
PITX2 and PANCR DNA methylation predicts overall survival in patients with head and neck squamous cell carcinoma
Verena Sailer, Emily Eva Holmes, Heidrun Gevensleben, et al.
The Journal of Molecular Diagnostics : JMD
|
March 23, 2010
Development of a diagnostic microarray assay to assess the risk of recurrence of prostate cancer based on PITX2 DNA methylation
Philipp Schatz, Dimo Dietrich, Thomas Koenig, et al.
Virchows Archiv : an International Journal of Pathology
|
November 27, 2014
Biliary intraepithelial neoplasia (BilIN) is frequently found in surgical margins of biliary tract cancer resection specimens but has no clinical implications
Hanno Matthaei, Philipp Lingohr, Anke Strässer, et al.
Clinical Epigenetics
|
November 22, 2019
Molecular and immune correlates of TIM-3 (HAVCR2) and galectin 9 (LGALS9) mRNA expression and DNA methylation in melanoma
Tobias A W Holderried, Luka de Vos, Emma Grace Bawden, et al.
Endocrine-Related Cancer
|
November 28, 2013
SOCS2 correlates with malignancy and exerts growth-promoting effects in prostate cancer
Julia Hoefer, Johann Kern, Philipp Ofer, et al.
BMC Cancer
|
June 3, 2010
CDO1 promoter methylation is a biomarker for outcome prediction of anthracycline treated, estrogen receptor-positive, lymph node-positive breast cancer patients
Dimo Dietrich, Manuel Krispin, Jörn Dietrich, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 18, 2015
The Immune Checkpoint Regulator PD-L1 Is Highly Expressed in Aggressive Primary Prostate Cancer
Heidrun Gevensleben, Dimo Dietrich, Carsten Golletz, et al.
Oncotarget
|
December 2, 2015
Integration of tissue metabolomics, transcriptomics and immunohistochemistry reveals ERG- and gleason score-specific metabolomic alterations in prostate cancer
Sebastian Meller, Hellmuth-A Meyer, Bianca Bethan, et al.
Clinical Chemistry
|
February 1, 2024
Circulating Cell-Free SHOX2 DNA Methylation Is a Predictive, Prognostic, and Monitoring Biomarker in Adjuvant and Palliative Anti-PD-1-Treated Melanoma
Simon Fietz, Eric Diekmann, Luka de Vos, et al.
Page
of 12
Search research articles
Search
Showing results (71-80 of 116) with videos related to
Sort By:
Page
of 12
Clinical Epigenetics
|
September 24, 2016
<i>SEPT9</i> and <i>SHOX2</i> DNA methylation status and its utility in the diagnosis of colonic adenomas and colorectal adenocarcinomas
Alexander Semaan, Anne van Ellen, Sebastian Meller, et al.
Oncotarget
|
October 8, 2016
PITX2 and PANCR DNA methylation predicts overall survival in patients with head and neck squamous cell carcinoma
Verena Sailer, Emily Eva Holmes, Heidrun Gevensleben, et al.
The Journal of Molecular Diagnostics : JMD
|
March 23, 2010
Development of a diagnostic microarray assay to assess the risk of recurrence of prostate cancer based on PITX2 DNA methylation
Philipp Schatz, Dimo Dietrich, Thomas Koenig, et al.
Virchows Archiv : an International Journal of Pathology
|
November 27, 2014
Biliary intraepithelial neoplasia (BilIN) is frequently found in surgical margins of biliary tract cancer resection specimens but has no clinical implications
Hanno Matthaei, Philipp Lingohr, Anke Strässer, et al.
Clinical Epigenetics
|
November 22, 2019
Molecular and immune correlates of TIM-3 (HAVCR2) and galectin 9 (LGALS9) mRNA expression and DNA methylation in melanoma
Tobias A W Holderried, Luka de Vos, Emma Grace Bawden, et al.
Endocrine-Related Cancer
|
November 28, 2013
SOCS2 correlates with malignancy and exerts growth-promoting effects in prostate cancer
Julia Hoefer, Johann Kern, Philipp Ofer, et al.
BMC Cancer
|
June 3, 2010
CDO1 promoter methylation is a biomarker for outcome prediction of anthracycline treated, estrogen receptor-positive, lymph node-positive breast cancer patients
Dimo Dietrich, Manuel Krispin, Jörn Dietrich, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 18, 2015
The Immune Checkpoint Regulator PD-L1 Is Highly Expressed in Aggressive Primary Prostate Cancer
Heidrun Gevensleben, Dimo Dietrich, Carsten Golletz, et al.
Oncotarget
|
December 2, 2015
Integration of tissue metabolomics, transcriptomics and immunohistochemistry reveals ERG- and gleason score-specific metabolomic alterations in prostate cancer
Sebastian Meller, Hellmuth-A Meyer, Bianca Bethan, et al.
Clinical Chemistry
|
February 1, 2024
Circulating Cell-Free SHOX2 DNA Methylation Is a Predictive, Prognostic, and Monitoring Biomarker in Adjuvant and Palliative Anti-PD-1-Treated Melanoma
Simon Fietz, Eric Diekmann, Luka de Vos, et al.
Page
of 12